Condition: Melanoma (Skin Cancer) · Sponsor: Peter MacCallum Cancer Centre, Australia
This study aims to capture information regarding the effect of immune checkpoint inhibitor (ICI) treatment for melanoma on reproductive organ function and sex hormone levels. You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with melanoma (Stage II, III or IV) and you are planning to receive ICI treatment. Additional criteria will apply dependent upon your biological sex characteristics. All participants who choose to enroll in this study will be asked to complete a series of questionnaires and provide blood at 4 of their scheduled treatment visits. These visits are anticipated to add 30 minutes to the scheduled visit time. Male participants will also be asked to provide semen samples at 2 of their scheduled treatment visits. These visits are anticipated to add an additional 30 minutes to the scheduled visit time. No additional or novel treatments will be offered to participants who choose to enroll in this study, this is an observational study only. It is hoped this research will contribute important information regarding the potential toxic effects of ICI treatment on sexual and reproductive function in patients with melanoma who are receiving ICI treatment.
This description comes directly from the study's public registry record.
Dr Wanda Cui, BMEDSCI, MBBS · +61 3 8559 5000 · wanda.cui@petermac.org
Christine Dijkstra, BSC, MPH · christine.dijkstra@petermac.org
Always discuss trial participation with your own doctor first.
| Melanoma Institute Australia | Sydney, New South Wales, Australia | Not Yet Recruiting |
| Princess Alexandra Hospital | Brisbane, Queensland, Australia | Not Yet Recruiting |
| Cairns Base Hospital | Cairns, Queensland, Australia | Not Yet Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Not Yet Recruiting |
| Austin Hospital | Melbourne, Victoria, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07138222